Drugs · acquisition-cost intelligence
Metformin
Metformin ER 750 mg· ingredient metforminBiguanides· METFORMIN HYDROCHLORIDE 750 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.05528
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other metformin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Metformin Hydrochloride | $0.02457 | −$0.03070 |
| Metformin | $0.02990 | −$0.02540 |
| metformin hydrochloride | $0.20083 | +$0.14560 |
| Metformin Hydrochloride | $0.34864 | +$0.29340 |
| Metformin Hydrochloride Oral Solution | $0.41741 | +$0.36210 |
| saxagliptin and metformin | $7.74 | +$7.68 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 76% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.